Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
- Industry News
- Technology
- Software
- Banking
- Automotive
- Energy
- More
- Drug Approvals
- Clinical Trial Calendar

Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard

Crypto
Cryptocurrency
Blockchain

Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies

Politics
US
World
White House
Elections
General News

Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard

Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health

Slide Shows

Entertainment
Top Stories
- Pop
- Rock
- Classic Rock
- Rap/Hip-Hop
- Country
- Alternative
- Oldies
- All Genre

Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services

Premium
Intelligent Investor
Biotech Investor NEW
Login

Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us

Business
Corp. News
- Latest Headlines
- Biotech
- Investors
- Stock Alerts
- IPOs
- M&A
Industry News
- Technology
- Software
- Banking
- Automotive
- Energy
- More
Corp. Calendars
Earnings Calendar
FDA Calendars
- Drug Approvals
- Clinical Trial Calendar
Ratings Changes
Economy
- US
- Europe
- Asia
- Global
- Economic Calendar
- Economic Scorecard
Crypto
- Cryptocurrency
- Blockchain
Markets
Market News
Politics
- US
- World
- White House
- Elections
- General News
Forex
Health
Health News
Slide Shows
Entertainment
Entertainment News
- Top Stories
Music News
- Pop
- Rock
- Classic Rock
- Rap/Hip-Hop
- Country
- Alternative
- Oldies
- All Genre
Content Licensing
Premium
More

Novo Nordisk B A/S (NOVOB.CO)

Novo Nordisk POSEIDON Study Finds High Prevalence Of Cardiovascular Inflammation In CVD Patients 5/26/2026 9:07:38 AM

Novo Nordisk POSEIDON Study Reveals Widespread CV Inflammation In Chronic Kidney Disease Patients 5/26/2026 8:33:37 AM

CHMP Issues Positive Opinion On Novo Nordisk's Wegovy 7.2 Mg For Obesity 5/23/2026 12:24:39 PM

Novo Nordisk's Wegovy Pill Wins CHMP Recommendation For Approval In EU 5/22/2026 11:57:31 AM

CHMP Recommends Novo Nordisk's Wegovy Pill As First Oral GLP-1 For Weight Management In EU 5/22/2026 10:32:49 AM

Novo Nordisk B A/S Q1 Income Climbs 5/6/2026 1:43:17 AM

Novo Nordisk Posts Adj Operating Profit Of DKK 32.858 Bln In Q1 5/6/2026 1:32:30 AM

Weekly Buzz: SNY, REGN Get FDA Nod; It's A No For ABBV, GRCE; LLY Acquires Kelonia 4/24/2026 10:34:13 AM

Novo Nordisk's Oral Semaglutide Shows Superior Blood Sugar Control In Youth-Onset Type 2 Diabetes 4/23/2026 7:06:42 AM

Novo Nordisk's Etavopivat Meets Co-primary Goals In Phase 3 HIBISCUS Trial In Sickle Cell Disease 4/20/2026 6:50:43 AM

Novo Nordisk Partners With OpenAI To Transform Drug Discovery And Delivery 4/14/2026 6:19:31 AM

GLP-1 Drugs Move Up The Leaderboard As Twin Epidemics Continue To Balloon 4/13/2026 4:30:46 AM

Weekly Buzz: SPRY Gains FDA Nod; EU Expands Kerendia Label; LLY Acquires CNTA; BIIB Snaps Up APLS 4/3/2026 5:10:06 AM

Novo Nordisk's Wegovy Approved For Cardiovascular Event Risk Reduction In England 4/1/2026 1:02:57 PM

U.K.'s NICE Endorses Novo Nordisk's Wegovy For Cardiovascular Risk Reduction Beyond Weight Loss 4/1/2026 10:38:46 AM

Novo Nordisk Wins FDA Nod For Awiqli, First Once-Weekly Basal Insulin 3/27/2026 10:14:06 AM

Weekly Buzz: CORT Wins FDA Nod In Cancer; MRK Acquires TERN; INSM Meets Trial Goals But VALN Misses 3/27/2026 9:42:17 AM

Triple-G Agonist UBT251 Lowers HbA1c By Up To 2.16% In Chinese Phase 2 Diabetes Trial 3/25/2026 7:06:46 AM

Novo Nordisk Says Triple Agonist UBT251 Shows Up To 2.16% HbA1c Reduction In Phase 2 Trial 3/25/2026 2:34:03 AM

NVO : Triple Agonist UBT251 Cuts HbA1c By 2.16% In Phase 2 Trial Among Type 2 Diabetes Patients 3/25/2026 2:08:55 AM

- 1
- 2
- Next »

Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us | Contact Us | Privacy | Sitemap